1. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259–266
2. Brandes AA (2003) State-of-the-art treatment of high-grade brain tumors. Semin Oncol 30: 4–9
3. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63: 38–41
4. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58: 4363–4367
5. Chinot O, Barrié M, Cournède A, Dufor H, Figarella-Branger D, Braguer D, Peragut JC, Grisoli F (2005) Phase II study of temozolomide (TMZ) administered on a 7 days on-7days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol, ASCO Annual Meeting Proc 23 (16S, Part I of II, June 1 Suppl): 1523